Quick update on earnings. Nothing earth shattering on Vidaza. Sales up 10% for quarter. US sales doing better than international. Thought it has been the other way around recently on sales mix. Will need to check my notes. No guidance in 2013 for Vidaza sales or clinical update. Have not listened to CC yet.
Costs to run Celg outpaced revenue increase. Samething will happen with astex, except one very important point, dacogen will go generic. CEO stated it himself, much easier to duplicate dacogen then vidaza. IR confirmed that dacogen will go generic in May and impact third quarter numbers. If Eisai revises dacogen sales down, this stock will feel some pain. They are spending $88M a year on expenses. I would prefer to own this in the low $4's. Much safer. Burn this year $30M plus an addittional $14M in the first quarter of 2014, plus the full impact of Dacogen generic will be felt in first quarter 2014 at the same time they have to dilute shares.